What are the major opportunities in the Hormone Refractory Prostate Cancer market? What are the strategies for the Hormone Refractory Prostate Cancer market?

For detailed insights on the major opportunities and strategies in the Hormone Refractory Prostate Cancer market, Read More

How does the Hormone Refractory Prostate Cancer market relate to the overall economy and other similar markets?

For detailed insights on Hormone Refractory Prostate Cancer's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Hormone Refractory Prostate Cancer market growth? SWOT analysis of the Hormone Refractory Prostate Cancer market.

For detailed insights on the key dynamics influencing the Hormone Refractory Prostate Cancer market growth and SWOT analysis of the Hormone Refractory Prostate Cancer industry, Read More

$Global Hormone Refractory Prostate Cancer Market Report 2025$

Item added to cart!

Published : December 2025

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Hormone Refractory Prostate Cancer Global Market Report 2025

Name: Hormone Refractory Prostate Cancer Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Treatment Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Hormone Refractory Prostate Cancer Market Overview

• Hormone Refractory Prostate Cancer market size has reached to $7.35 billion in 2024

• Expected to grow to $11.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%

• Growth Driver: A Growing Investment In Cancer Research Worldwide Is Fueling The Growth Of The Market Due To Increasing Focus On Advanced Therapies And Precision Treatment Development

• Market Trend: Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hormone Refractory Prostate Cancer Market?

Hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC), is a form of prostate cancer that continues to progress despite achieving low testosterone levels through androgen deprivation therapy (ADT). This progression may be indicated by rising prostate-specific antigen (PSA) levels, radiographic evidence of new or growing tumors, or worsening clinical symptoms. Hormone-refractory prostate cancer (HRPC) represents a more advanced and treatment-resistant stage of prostate cancer, often requiring additional systemic therapies beyond standard hormone suppression.

The main treatment types for hormone-refractory prostate cancer are chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy treats hormone-refractory prostate cancer by using powerful drugs to target cancer that no longer responds to hormone therapy and has spread. It is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, including hospitals, ambulatory surgical centers, specialty clinics, and others.

$Hormone Refractory Prostate Cancer Market Size and growth rate 2025 to 2029: Graph$

What Is The Hormone Refractory Prostate Cancer Market Size 2025 And Growth Rate?

The hormone-refractory prostate cancer market size has grown rapidly in recent years. It will grow from $7.35 billion in 2024 to $8.12 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing incidence of prostate cancer, a rise in PSA (prostate-specific antigen) screening, an increase in physician awareness and specialization, increasing palliative care use, and an increasing number of clinical trials.

What Is The Hormone Refractory Prostate Cancer Market Growth Forecast?

The hormone-refractory prostate cancer market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing use of genetic biomarkers, rising adoption of precision medicine, expansion of PARP inhibitors, increasing global access to HRPC treatments, and growing clinical adoption of combination regimens. Major trends in the forecast period include adoption of combination therapies, advancement in radiopharmaceuticals, use of next-generation sequencing (NGS), digital tools and remote monitoring integration, and development of next-generation androgen receptor inhibitors and PARP inhibitors for HRPC.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Hormone Refractory Prostate Cancer Market Segmented?

1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin

2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists

3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy

5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)

What Is Driving The Hormone Refractory Prostate Cancer Market? A Growing Investment In Cancer Research Worldwide Is Fueling The Growth Of The Market Due To Increasing Focus On Advanced Therapies And Precision Treatment Development

A growing investment in cancer research is expected to propel the growth of the hormone-refractory prostate cancer market going forward. Cancer research investment involves funding and resource support to advance innovative cancer detection, treatment, and prevention approaches. The cancer research investment is rising due to the increasing global cancer burden, which demands more effective and targeted treatments. Investment in cancer research drives innovation in treating hormone-refractory prostate cancer by enabling advanced therapies such as radioligand treatments and hormone inhibitors. It also funds clinical trials and biomarker research to enhance treatment precision and outcomes. For instance, in August 2024, according to the Cancer Research Institute (CRI), a US-based nonprofit organization dedicated to advancing immunotherapy research, invested around $22.8 million in the 2023–2024 fiscal year, funding 64 new grants to researchers from 42 institutions across seven countries. Therefore, growing investment in cancer research is driving the growth of the hormone-refractory prostate cancer industry.

Who Are The Major Players In The Global Hormone Refractory Prostate Cancer Market?

Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC

What Are The Key Trends Of The Global Hormone Refractory Prostate Cancer Market? Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer

Major companies operating in the hormone-refractory prostate cancer market are focusing on developing advanced therapies, such as intravenous radioligand therapy, to improve survival rates in patients with resistant forms of the disease. Intravenous radioligand therapy is a targeted treatment that uses radioactive molecules attached to ligands to identify and bind to cancer-specific markers. It destroys cancer cells internally while sparing surrounding healthy tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical corporation, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received approval from the Food and Drug Administration (FDA). It is designed for earlier use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) and are appropriate to delay chemotherapy. The expanded indication, based on the Phase III PSMAfore trial, approximately triples the eligible patient population and showed that Pluvicto reduced the risk of radiographic progression or death by 59% and more than doubled median radiographic progression-free survival compared to a change in ARPI. Pluvicto is the first targeted radioligand therapy approved for use before chemotherapy in this setting, offering a new treatment option that delays disease progression with a favorable safety profile.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market? Astrazeneca Acquired Fusion Pharmaceuticals To Boost Radiopharmaceutical Cancer Therapies

In June 2024, AstraZeneca, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.4 billion. This acquisition aims to enhance AstraZeneca’s oncology portfolio by adding next-generation radioconjugate therapies, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC), and to strengthen its capabilities in radiopharmaceutical research and development, manufacturing, and supply. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company that provides treatment for metastatic castration-resistant prostate cancer.

What Is The Regional Outlook For The Global Hormone Refractory Prostate Cancer Market?

North America was the largest region in the acute care telemedicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Care Telemedicine Market?

The acute care telemedicine market includes revenues earned by entities by providing services like virtual emergency care, remote intensive care unit monitoring, tele-stroke evaluations, virtual hospitalist support, and real-time specialist consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Hormone Refractory Prostate Cancer Industry?

The hormone refractory prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including the hormone refractory prostate cancer global market size, regional shares, competitors with the market share, detailed market segments, market trends, opportunities, and any further data you may need to thrive in the hormone refractory prostate cancer industry. This market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abdul Wasay

Hormone Refractory Prostate Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$8.12 billion
Revenue Forecast In 2034	$11.91 billion
Growth Rate	CAGR of 10.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	Treatment Type, Distribution Channel, End-User, Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Hormone Refractory Prostate Cancer Market Characteristics

3. Hormone Refractory Prostate Cancer Market Trends And Strategies

4. Hormone Refractory Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hormone Refractory Prostate Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Hormone Refractory Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Hormone Refractory Prostate Cancer Market Growth Rate Analysis

5.4. Global Hormone Refractory Prostate Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Hormone Refractory Prostate Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Hormone Refractory Prostate Cancer Total Addressable Market (TAM)

6. Hormone Refractory Prostate Cancer Market Segmentation

6.1. Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy

Hormonal Therapy

Immunotherapy

Radiation Therapy

Surgery

6.2. Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.3. Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Other End-Users

6.4. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Docetaxel

Cabazitaxel

Mitoxantrone

Estramustine

6.5. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anti-Androgens

CYP17 Inhibitors

LHRH Agonists

LHRH Antagonists

6.6. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cancer Vaccines

Immune Checkpoint Inhibitors

Adoptive Cell Therapy

6.7. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

External Beam Radiation Therapy (EBRT)

Brachytherapy

Radionuclide Therapy

6.8. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Radical Prostatectomy

Orchiectomy

Transurethral Resection Of The Prostate (TURP)

7. Hormone Refractory Prostate Cancer Market Regional And Country Analysis

7.1. Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hormone Refractory Prostate Cancer Market

8.1. Asia-Pacific Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hormone Refractory Prostate Cancer Market

9.1. China Hormone Refractory Prostate Cancer Market Overview

9.2. China Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hormone Refractory Prostate Cancer Market

10.1. India Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hormone Refractory Prostate Cancer Market

11.1. Japan Hormone Refractory Prostate Cancer Market Overview

11.2. Japan Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hormone Refractory Prostate Cancer Market

12.1. Australia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hormone Refractory Prostate Cancer Market

13.1. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hormone Refractory Prostate Cancer Market

14.1. South Korea Hormone Refractory Prostate Cancer Market Overview

14.2. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hormone Refractory Prostate Cancer Market

15.1. Western Europe Hormone Refractory Prostate Cancer Market Overview

15.2. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hormone Refractory Prostate Cancer Market

16.1. UK Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hormone Refractory Prostate Cancer Market

17.1. Germany Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hormone Refractory Prostate Cancer Market

18.1. France Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hormone Refractory Prostate Cancer Market

19.1. Italy Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hormone Refractory Prostate Cancer Market

20.1. Spain Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hormone Refractory Prostate Cancer Market

21.1. Eastern Europe Hormone Refractory Prostate Cancer Market Overview

21.2. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hormone Refractory Prostate Cancer Market

22.1. Russia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hormone Refractory Prostate Cancer Market

23.1. North America Hormone Refractory Prostate Cancer Market Overview

23.2. North America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hormone Refractory Prostate Cancer Market

24.1. USA Hormone Refractory Prostate Cancer Market Overview

24.2. USA Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hormone Refractory Prostate Cancer Market

25.1. Canada Hormone Refractory Prostate Cancer Market Overview

25.2. Canada Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hormone Refractory Prostate Cancer Market

26.1. South America Hormone Refractory Prostate Cancer Market Overview

26.2. South America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hormone Refractory Prostate Cancer Market

27.1. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hormone Refractory Prostate Cancer Market

28.1. Middle East Hormone Refractory Prostate Cancer Market Overview

28.2. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hormone Refractory Prostate Cancer Market

29.1. Africa Hormone Refractory Prostate Cancer Market Overview

29.2. Africa Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hormone Refractory Prostate Cancer Market Competitive Landscape And Company Profiles

30.1. Hormone Refractory Prostate Cancer Market Competitive Landscape

30.2. Hormone Refractory Prostate Cancer Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hormone Refractory Prostate Cancer Market Other Major And Innovative Companies

31.1. Bayer AG

31.2. Sanofi S.A.

31.3. Bristol-Myers Squibb Company

31.4. Novartis AG

31.5. AstraZeneca plc

31.6. Takeda Pharmaceutical Company Limited

31.7. Eli Lilly and Company

31.8. Amgen Inc.

31.9. Astellas Pharma Inc.

31.10. Ipsen Pharma

31.11. Exelixis Inc.

31.12. Orion Corporation

31.13. Lantheus Holdings Inc.

31.14. Clovis Oncology Inc.

31.15. Telix Pharmaceuticals

32. Global Hormone Refractory Prostate Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market

34. Recent Developments In The Hormone Refractory Prostate Cancer Market

35. Hormone Refractory Prostate Cancer Market High Potential Countries, Segments and Strategies

35.1 Hormone Refractory Prostate Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 Hormone Refractory Prostate Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 Hormone Refractory Prostate Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Pfizer Inc. Financial Performance

Table 80: Johnson And Johnson Financial Performance

Table 81: F. Hoffmann-La Roche Ltd. Financial Performance

Table 82: Merck & Co. Inc. Financial Performance

Table 83: AbbVie Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Pfizer Inc. Financial Performance

Figure 80: Johnson And Johnson Financial Performance

Figure 81: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 82: Merck & Co. Inc. Financial Performance

Figure 83: AbbVie Inc. Financial Performance

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Prostate Cancer Diagnostics Global Market Report 2025 – By Products (Instruments, Reagents And Consumables, Accessories), By Test Type (Preliminary Tests, Confirmatory Tests), By Prostate Cancer (Squamous Cell Cancer, Sm...

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025 – By Type (Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)), By Test Type (Preliminary Tests, Confirmat...

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2025 – By Product (Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants), By Procedure Type (Tr...

Drugs For Benign Prostatic hypertrophy Global Market Report 2025 – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Ph...

Urinary Tract Cancer Global Market Report 2025 – By Cancer Type (Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer), By Treatment (Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery), By Diagn...

Prostate Specific Antigen (PSA) Test Global Market Report 2025 – By Type (Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Types), By App...

Hormone Therapy Global Market Report 2025 – By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement), By Route of Administration (Oral, Parenteral, Othe...

Frequently Asked Questions

What is the definition of the Hormone Refractory Prostate Cancer market?

How will the Hormone Refractory Prostate Cancer market drivers and restraints affect the market dynamics? What forces will shape the Hormone Refractory Prostate Cancer industry going forward?

The Hormone Refractory Prostate Cancer market major growth driver - A Growing Investment In Cancer Research Worldwide Is Fueling The Growth Of The Market Due To Increasing Focus On Advanced Therapies And Precision Treatment Development. For further insights on the Hormone Refractory Prostate Cancer market, request a sample here

What is the forecast market size or the forecast market value of the Hormone Refractory Prostate Cancer market?

The Hormone Refractory Prostate Cancer market size has grown strongly in recent years. The hormone-refractory prostate cancer market size has grown rapidly in recent years. It will grow from $7.35 billion in 2024 to $8.12 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing incidence of prostate cancer, a rise in PSA (prostate-specific antigen) screening, an increase in physician awareness and specialization, increasing palliative care use, and an increasing number of clinical trials. The hormone-refractory prostate cancer market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing use of genetic biomarkers, rising adoption of precision medicine, expansion of PARP inhibitors, increasing global access to HRPC treatments, and growing clinical adoption of combination regimens. Major trends in the forecast period include adoption of combination therapies, advancement in radiopharmaceuticals, use of next-generation sequencing (NGS), digital tools and remote monitoring integration, and development of next-generation androgen receptor inhibitors and PARP inhibitors for HRPC. For further insights on the Hormone Refractory Prostate Cancer market, request a sample here

How is the Hormone Refractory Prostate Cancer market segmented?

The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP) For further insights on the Hormone Refractory Prostate Cancer market, request a sample here

Which region has the largest share of the Hormone Refractory Prostate Cancer market? What are the other regions covered in the report?

North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Hormone Refractory Prostate Cancer market, request a sample here.

Who are the major players in the Hormone Refractory Prostate Cancer market?

What are the key trends in the Hormone Refractory Prostate Cancer market?

Major trends in the Hormone Refractory Prostate Cancer market include Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer. For further insights on the Hormone Refractory Prostate Cancer market, request a sample here.